Q4W有效性完胜Q2W,这个这么解释?
In Stage 2, patients that achieved EASI-50 (responders) regardless of initial treatment in the 16-week Stage 1 were randomized to either dosing every two weeks (“Q2W”) rademikibart (n=113) or dosing every four weeks (“Q4W”) rademikibart (n=112) arms. Patients that did not achieve EASI-50 (non-responders) were assigned to an open label Q2W rademikibart arm (n=86).
公告的不怎么有效的患者数量是86人,不是26人。
除非同期公布不那么有效人群(即16周没达到EASI-50)的Q2W组数据,否则个人认为无比较意义。